Skip to main content
Journal of Global Oncology logoLink to Journal of Global Oncology
. 2018 Nov 6;4:JGO.17.00229. doi: 10.1200/JGO.17.00229

Feasibility of Patient Navigation to Improve Breast Cancer Care in Malaysia

Zi-Yi Yeoh 1, Maheswari Jaganathan 1, Nadia Rajaram 1, Sudha Rawat 1, Nurul Ain Tajudeen 1, Norlia Rahim 1, Nur Hidayati Zainal 1, Sakthi Maniam 1, Ushananthiny Suvelayutnan 1, Rahani Yaacob 1, Vijayalakshmi Krishnapillai 1, Meor Zamari Meor Kamal 1, Soo-Hwang Teo 1,, Mohamed Yusof Abdul Wahab 1
PMCID: PMC7010457  PMID: 30398950

Abstract

Purpose

Late stage at presentation and poor adherence to treatment remain major contributors to poor survival in low- and middle-income countries (LMICs). Patient navigation (PN) programs in the United States have led to improvement in diagnostic or treatment timeliness, particularly for women in lower socioeconomic classes or minority groups. To date, studies of PN in Asia have been limited. We aimed to assess the feasibility of PN in a state-run hospital in an LMIC and to report the impact on diagnostic and treatment timeliness for patients in its first year of implementation.

Methods

We established PN in a dedicated breast clinic of a Malaysian state-run hospital. We compared diagnostic and treatment timeliness between navigated patients (n = 135) and patients diagnosed in the prior year (n = 148), and described factors associated with timeliness.

Results

Women with PN received timely mammography compared with patients in the prior year (96.4% v 74.4%; P < .001), biopsy (92.5% v 76.1%; P = .003), and communication of news (80.0% v 58.5%; P < .001). PN reduced treatment default rates (4.4% v 11.5%; P = .048). Among navigated patients, late stage at presentation was independently associated with having emotional and language barriers (P = .01). Finally, the main reason reported for delay, default, or refusal of treatment was the preference for alternative therapy.

Conclusion

PN is feasible for addressing barriers to cancer care when integrated with a state-run breast clinic of an LMIC. Its implementation resulted in improved diagnostic timeliness and reduced treatment default. Wider adoption of PN could be a key element of cancer control in LMICs.

INTRODUCTION

Breast cancer is a major public health burden in Asia. In Malaysia, the age-standardized incidence rate is 38.7 per 100,000 women per year, and the number of patients with breast cancer are projected to continue increasing.1 Notably, Malaysian patients with breast cancer have one of the lowest survival rates in the Asia-Pacific region, with a 5-year survival of only 49%,1,2 compared with up to 90% in the United States.3

A major reason for poor survival among Malaysian women is late presentation (43% of breast cancers present at stages III and IV).4 Past research in Malaysia has shown that patients with breast cancer attending subsidized services at public hospitals have higher mortality compared with patients attending private hospitals (hazard ratio, 1.59; 95% CI, 1.36 to 1.85),5 and this is likely driven by differences in patient socioeconomic status. Women of lower socioeconomic status have more high-risk health behaviors, poorer nutritional status, and poorer health literacy, and are less likely to receive screening and treatment.6 Taken together, this suggests that focusing on achieving timely diagnosis and treatment completion, particularly among lower income groups, is a key priority in improving breast cancer survivorship in the region.

Patient navigation (PN) is a patient-centered approach to improving health care delivery by promoting timely movement of a patient through a complex health care continuum.7 PN serves to improve coordination of the health care system and, on an individual level, helps patients overcome barriers to cancer care. A systematic review in 2016 showed that PN improved diagnostic timeliness and helped women receive proper treatment for breast cancer.8 Some studies showed improved diagnostic timeliness only in a subgroup of women, namely, older women,9 Asian or Hispanic women paired with an Asian or Hispanic navigator,10 or women who were most likely to experience delays in diagnostic resolution.11 PN also improved overall adherence to quality care indicators12 and decreased cancer-related distress.13 By addressing barriers to cancer care, PN could improve breast cancer survival in LMICs, particularly among women in lower socioeconomic groups.

PN could be an effective approach to improving breast cancer care in Asia, but its implementation in the different cultural and resource settings in the region is not well studied. Case studies in Singapore, Nepal, and India have highlighted the challenges of executing PN, including difficulties in coordinating care and inefficiencies in patient flow, and pointed to factors that delay care, such as financial constraints and low health literacy.14-16 However, no study has determined the impact of PN on patient outcomes in Asia.

We integrated PN in a breast clinic, the Pink Ribbon Centre (PRC), in a suburban state-run secondary referral hospital (Hospital Tengku Ampuan Rahimah, Klang, Malaysia). In this article, we report the feasibility of PN in this state-run hospital in an LMIC. We also assessed whether PN improved diagnostic and treatment timeliness for patients in its first year of implementation, compared with patients with breast cancer diagnosed in the previous year.

METHODS

Patients With Breast Cancer

From November 2014 to December 2015, 225 women were referred to the PRC from the hospitals' surgical outpatient clinics. All patients diagnosed with breast cancer (N = 146) were recruited to the PN program. The study was approved by the Malaysian Research Ethics Committee (NMRR-17-2951-35223), and permission to use patient data was sought from the hospital under the governance of the Malaysian Ministry of Health.

Patient Navigation

We trained three qualified nurses in general nursing, oncology, and breast care and surgery as nurse navigators in the PRC. Navigators aimed to improve diagnostic and treatment timeliness, reduce default rates, and increase treatment completion rates. To achieve these aims, navigators were trained to provide patient and family education, supportive care and visits, and practical help in overcoming individual patient barriers. A community navigator addressed patients’ social welfare needs that hinder completion of cancer care.

In addition, the PRC had an assigned surgical medical officer, increased clinic days, dedicated phone lines, and implemented e-tracking and appointment reminder calls. There were service-level agreements with the radiology and pathology departments for increased service allocations. Patients with early-stage breast cancer received a culturally relevant decision aid tool to enhance shared decision making.

Data Collection

At the first PRC visit, navigators administered a baseline questionnaire to collect patient data and identify potential barriers to cancer care. The navigators’ workload was recorded at the end of every week. Using an e-tracking system, we collated patient milestones, which were used to determine referral timeliness (time from referral to first visit at the PRC), diagnostic timeliness (time from the first visit to the communication of diagnosis), and treatment initiation timeliness (time from diagnosis to surgery or the initiation of neoadjuvant treatment, whichever was first). Defaulters were defined as patients with breast cancer who were lost to follow-up before treatment initiation and were not contactable or refused contact with the PRC. Data for patients from the year before the PN program began were obtained. In addition, the surgical medical officer collected information on cancer stage, treatment received, and reasons for treatment delays, if available.

Statistical Analysis

Standard descriptive statistics were used to describe the cohort. We assessed the effect of PN on diagnostic and treatment timeliness, using state-defined key performance indicators,17 by comparing the navigated cohort with patients with breast cancer from the preceding year. Factors associated with cancer stage were assessed using Wilcoxon rank sum tests for continuous data and Fisher’s exact test for categorical data. Multivariable logistic regression was used to determine the independent predictors of late stage at presentation. All analyses were two-sided, and P values < .05 were considered statistically significant. All statistical tests were performed using the R statistical environment version 3.4.0. Patient notes were transcribed and analyzed for the subset of women who had delayed, refused, or defaulted on primary treatment.

RESULTS

Cohort

We describe here the feasibility and performance of PN for patients with breast cancer in a Malaysian suburban state-run hospital. From November 2014 to December 2015, 225 women were referred to the PRC from the surgical outpatient department. All women diagnosed with breast cancer (N = 146) were included in the analysis, excluding women who received surgical treatment (n = 8) or who died (n = 3) before visiting PRC. We report the outcomes for these 135 women up to completion of treatment, treatment default, death, or to December 31, 2016. The care pathway is described in Appendix Figure A1.

The baseline demographic characteristics of the 135 patients with breast cancer diagnosed in the first year are listed in Table 1. The median age was 53.0 years (interquartile range, 46.5 to 62.0 years). Half of patients (50.4%) were ethnically Malay, 28.1% were Indian, and 19.3% were Chinese. Most patients (61.5%) did not complete secondary education. The median monthly household income was US $467 (interquartile range, $234 to $701). More than one in six women (17.8%) lived below the national poverty line (≤ US $187/month). Nearly half (48.9%) were diagnosed with late-stage disease (stage III or IV).

Table 1.

Baseline Demographic Characteristics of Patients (n = 135)

graphic file with name JGO.17.00229t1.jpg

The barriers to cancer care that were identified by navigators and reported by patients are listed in Table 2. The most common barrier was poor breast health literacy (97.0%). We found that half of the patients (61.5%) could not name a sign of breast cancer, 74.8% could not name a risk factor, 68.1% did not know about available screening services, and 74.8% did not know the recommended age to start screening. Other barriers identified by the navigators included logistic (38.5%), financial (38.5%), emotional (35.6%), and communication barriers (23.7%).

Table 2.

Potential Barriers to Cancer Care (n = 135)

graphic file with name JGO.17.00229t2.jpg

Women presenting with late-stage breast cancer were more likely to have emotional barriers (45.5% v 26.1%; P = .021), preferred to speak or read in languages other than English (19.7% v 36.2%; P = .036; and 16.7% v 31.9%; P = .045, respectively), had lower monthly household incomes (US $350 v $540; P = .023), were interdepartmental referrals (31.8% v 14.5%; P = .044), and were less likely to have their own transport (36.4% v 56.5%; P = .048; Table 3). Our model using multivariable logistic regression (Appendix Table A1) showed that late stage at presentation was independently associated with having emotional and language barriers.

Table 3.

Factors Associated With Late-Stage Breast Cancer

graphic file with name JGO.17.00229t3.jpg

Operations

We listed the navigators’ workload for the year in Table 4. Nearly half of the patients (40.0%) received referrals for social welfare support. More than one in six patients (17.0%) received community navigation, including support for transportation, financial aid, food, and legal assistance.

Table 4.

Navigator Workload

graphic file with name JGO.17.00229t4.jpg

Impact of PN

We assessed diagnostic and treatment timeliness with PN (Table 5). There were significant improvements with PN compared with the year before in timeliness for mammogram (0 v 1 day; P < .001), timeliness of biopsy (0 v 1 day; P < .001), and communication of news (11 v 13 days; P = .001). Time to surgery decreased from 27.0 to 22.0 days (P = .121) with PN, but time to neoadjuvant therapy increased from 25.0 to 38.0 days (P = .133).

Table 5.

Diagnostic and Treatment Timeliness With Patient Navigation

graphic file with name JGO.17.00229t5.jpg

In Table 6, the proportion of women meeting state-defined key performance indicators on diagnostic and treatment timeliness were significantly improved for mammography (96.4% v 74.4%; P < .001), biopsy (92.5% v 76.1%; P = .003), and communication of news (80.0% v 58.5%; P < .001) with PN. The proportion of patients who defaulted before treatment decreased significantly, from 11.5% to 4.4% with PN (P = .048).

Table 6.

State-Defined Key Performance Indicators With Patient Navigation

graphic file with name JGO.17.00229t6.jpg

Factors Associated With Delay, Refusal, or Default of Primary Treatment

For 14 of the 50 patients who delayed, refused, or defaulted on primary treatment, qualitative analysis of patient notes highlighted four themes: belief in alternative therapy (n = 9), fear of treatment adverse effects (n = 2), family influence on health care decision (n = 2), and delaying treatment for a life or social event (n = 2). We observed that many women delayed or refused medical treatment in favor of alternative therapy, including local traditional medicine, Chinese medicine, and nutritional supplements.

DISCUSSION

We show that PN improves diagnostic and treatment metrics for patients and is feasible in a dedicated breast clinic of a hospital in an LMIC. To our knowledge, this is the first PN report on quantitative outcomes in an LMIC. This study shows the success of PN in improving timely diagnosis, reducing treatment default, and achieving state-defined key performance indicators.

The ability of PN to improve diagnostic resolution is supported by strong evidence in the United States.8 The beneficial effect of PN was greatest among patients with the most challenges in diagnostic resolution, such as in at-risk populations that faced greater financial, health care, and social service barriers.18,19 Furthermore, a ceiling effect was observed where PN had little or no impact when the baseline diagnostic resolution rates were 90% or greater.14 Collectively, this indicates that PN programs can be used to improve diagnostic resolution rates and timeliness for patients with breast cancer facing specific barriers to cancer care.

Consistent with previous literature, we did not observe improvements in treatment timeliness with PN.20 A systematic review examined seven studies from 1990 to 2015 that investigated improvements in breast cancer treatment initiation with PN.20 The majority of studies (five of seven) did not show any statistically significant impact.20 The two studies that showed a significant impact were PN programs in a medically underserved population in the United States, such as women in extreme poverty and in geographically isolated areas.20 Malaysia uses a universal health care system that subsidizes services to all citizens, making health care affordable and accessible for most of the population. It is possible that, in our study population, the cost of treatment is not the main barrier to treatment initiation.

We propose that the reduction in treatment default rates was the main benefit of PN in our population. Consistent with our finding, PN has also been shown to significantly reduce no-show rates for colposcopy after an abnormal cervical smear (49.7% v 29.5% with PN, P < .001).21 Patient default is associated with the lack of psychological support, logistic or physical difficulty in accessing health care, and patient preference for female doctors.22-24 These barriers can be actively overcome with PN.

Belief in alternative therapy was the most common reason to delay, default on, or refuse treatment.25 In Malaysia, patients with breast cancer are often offered unsolicited advice and sometimes coerced into using alternative medicine by family and friends.26,27 The other reasons for seeking alternative therapy include the belief that modern treatment offers poor life quality and the need for emotional support in the face of denial.26 Through our experience, nurse navigators can play a crucial role in alleviating these barriers by acknowledging cultural beliefs, providing emotional support and consistent communication, and improving health literacy, thereby empowering women to make informed decisions about their treatment.

We observed that some women presented to the emergency, medical, or orthopedics departments before arrival at the PRC. These women were more likely to be unaware of or were in denial about their breast cancer and therefore were more likely to present in crisis mode and at later stages. This highlights the need for better general awareness of the signs and symptoms of breast cancer and improved health literacy in the community. Therefore, to improve survival from breast cancer, there is an urgent need to address the issue of late presentation, such as by expanding PN to include innovative community interventions that address population-specific and/or culture-specific barriers.

Although ours was a prospective study, it may be subject to bias because we used a historical comparison without full follow-up data. Furthermore, half of the navigated women were unable to use the culturally relevant decision aid tool in the decision-making process, which was designed for patients with early-stage breast cancer. However, to our knowledge, this is the first quantitative study of PN in an LMIC. Importantly, this PN program ensured cultural acceptability by employing multilingual, trained hospital nurses as navigators. Our findings suggest that PN, if implemented nationally and tailored for cultural sensitivity, may improve outcomes for patients with breast cancer in Malaysia. PN integrated into a breast clinic in a Malaysian state-run hospital is feasible and successful in improving diagnostic timeliness and reducing treatment default, but its effect on timely treatment initiation, treatment adherence, and survival requires additional investigation.

ACKNOWLEDGMENT

For their support and contribution to this study, we thank the management and team from Hospital Tengku Ampuan Rahimah (HTAR), including but not limited to Mahesan Sukumaran, MD; Ding May Ling, MD; Kiran Kaur, MD; Dhiauddin Hai Ismail, MD; Anitha Haniffa, MD; Ku Halip (Medical Social Welfare Department); Matron Rusiah; Matron Siti Aisyah; Matron Nadia Renu; and Sister Hamiza. We thank all staff at the Oncology Day Care Department, Nursing Department, Physiotherapy and Occupational Therapy Department, Dietitian Department, and Surgical Wards of HTAR. In addition, we thank the Oncology Department of Hospital Kuala Lumpur, the Nuclear Medicine Department of the National Institute of Cancer Malaysia, and the Oncology and Radiology Department of Sri Kota Medical Centre for their cooperation. We also thank our community partners for their commitment to our patients, including the National Cancer Council Malaysia (Majlis Kanser Nasional), Grace Community, Tzu Chi, Selangor Water Supply Company (SYABAS), Insolvency Malaysia, Shah Alam High Court, Malayan Banking Berhad, Public Bank Berhad, the Poor Students' Trust Fund, local schools and Parent-Teacher Associations, and ZAKAT. We thank the Director General of Health Malaysia for his permission to publish this article. The PN program is supported by the funds raised through the Sime Darby Ladies Pro Golf Association Tournament. Finally, this work would not be possible without the patience and cooperation of the patients with breast cancer at HTAR.

Appendix

Fig A1.

Fig A1

Patient flow and timeline in the patient navigation (PN) program. (*)Patients who died before the first visit (n = 3), received surgical treatment before arriving at Pink Ribbon Centre (PRC; n = 8). (†)Transferred to other hospitals (n = 17), unsuitable for primary treatment (n = 8), defaulted treatment (n = 6), refused treatment (n = 4), and died before treatment initiation (n = 2).

Table A1.

Multivariable Analysis of Factors Associated With Late Stage at Presentation

graphic file with name JGO.17.00229ta1.jpg

AUTHOR CONTRIBUTIONS

Conception and design: Zi-Yi Yeoh, Maheswari Jaganathan, Sudha Rawat, Ushananthiny Suvelayutnan, Rahani Yaacob, Vijayalakshmi Krishnapillai, Soo-Hwang Teo, Mohamed Yusof Abdul Wahab

Administrative support: Nurul Ain Tajudeen, Norlia Rahim, Rahani Yaacob, Vijayalakshmi Krishnapillai, Mohamed Yusof Abdul Wahab

Provision of study materials or patients: Meor Zamari Meor Kamal

Collection and assembly of data: Zi-Yi Yeoh, Maheswari Jaganathan, Sudha Rawat, Nurul Ain Tajudeen, Norlia Rahim, Nur Hidayati Zainal, Sakthi Maniam, Ushananthiny Suvelayutnan, Soo-Hwang Teo, Mohamed Yusof Abdul Wahab

Data analysis and interpretation: Zi-Yi Yeoh, Maheswari Jaganathan, Nadia Rajaram, Ushananthiny Suvelayutnan, Meor Zamari Meor Kamal, Soo-Hwang Teo, Mohamed Yusof Abdul Wahab

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc.

Zi-Yi Yeoh

No relationship to disclose

Maheswari Jaganathan

No relationship to disclose

Nadia Rajaram

No relationship to disclose

Sudha Rawat

No relationship to disclose

Nurul Ain Tajudeen

No relationship to disclose

Norlia Rahim

No relationship to disclose

Nur Hidayati Zainal

No relationship to disclose

Sakthi Maniam

No relationship to disclose

Ushananthiny Suvelayutnan

No relationship to disclose

Rahani Yaacob

No relationship to disclose

Vijayalakshmi Krishnapillai

No relationship to disclose

Meor Zamari Meor Kamal

No relationship to disclose

Soo-Hwang Teo

Speakers' Bureau: AstraZeneca

Mohamed Yusof Abdul Wahab

No relationship to disclose

REFERENCES

  • 1.Ferlay J, Soerjomataram I, Ervik M, et al. http://publications.iarc.fr/Databases/Iarc-Cancerbases/GLOBOCAN-2012-Estimated-Cancer-Incidence-Mortality-And-Prevalence-Worldwide-In-2012-V1.0-2012
  • 2.Abdullah NA, Wan Mahiyuddin WR, Muhammad NA, et al. Survival rate of breast cancer patients in Malaysia: A population-based study. Asian Pac J Cancer Prev. 2013;14:4591–4594. doi: 10.7314/apjcp.2013.14.8.4591. [DOI] [PubMed] [Google Scholar]
  • 3.Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975-2013. https://seer.cancer.gov/csr/1975_2013/
  • 4.Manan A, Tamin N, Abdullah N, et al.
  • 5.Kong Y, Bhoo-Pathy N, Subramaniam S, et al. Advanced stage at presentation remains a major factor contributing to breast cancer survival disparity between public and private hospitals in a middle-income country. Int J Environ Res Public Health. 2017;14:427. doi: 10.3390/ijerph14040427. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Woods LM, Rachet B, Coleman MP. Origins of socio-economic inequalities in cancer survival: A review. Ann Oncol. 2006;17:5–19. doi: 10.1093/annonc/mdj007. [DOI] [PubMed] [Google Scholar]
  • 7.Freeman HP. The origin, evolution, and principles of patient navigation. Cancer Epidemiol Biomarkers Prev. 2012;21:1614–1617. doi: 10.1158/1055-9965.EPI-12-0982. [DOI] [PubMed] [Google Scholar]
  • 8.Krok-Schoen JL, Oliveri JM, Paskett ED. Cancer care delivery and women’s health: The role of patient navigation. Front Oncol. 2016;6:2. doi: 10.3389/fonc.2016.00002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Basu M, Linebarger J, Gabram SG, et al. The effect of nurse navigation on timeliness of breast cancer care at an academic comprehensive cancer center. Cancer. 2013;119:2524–2531. doi: 10.1002/cncr.28024. [DOI] [PubMed] [Google Scholar]
  • 10.Charlot M, Santana MC, Chen CA, et al. Impact of patient and navigator race and language concordance on care after cancer screening abnormalities. Cancer. 2015;121:1477–1483. doi: 10.1002/cncr.29221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Freund KM, Battaglia TA, Calhoun E, et al. Impact of patient navigation on timely cancer care: The Patient Navigation Research Program. J Natl Cancer Inst. 2014;106:dju115. doi: 10.1093/jnci/dju115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Chen F, Mercado C, Yermilov I, et al. Improving breast cancer quality of care with the use of patient navigators. Am Surg. 2010;76:1043–1046. [PubMed] [Google Scholar]
  • 13.Madore S, Kilbourn K, Valverde P, et al. Feasibility of a psychosocial and patient navigation intervention to improve access to treatment among underserved breast cancer patients. Support Care Cancer. 2014;22:2085–2093. doi: 10.1007/s00520-014-2176-5. [DOI] [PubMed] [Google Scholar]
  • 14.Mustapha NZB, Yi X, Mohd Razali MRB, et al. The role of patient navigators: Case studies in Singapore. Proc Singapore Healthc. 2016;25:188–190. [Google Scholar]
  • 15.Raut A, Thapa P, Citrin D, et al. Design and implementation of a patient navigation system in rural Nepal: Improving patient experience in resource-constrained settings. Healthc (Amst) 2015;3:251–257. doi: 10.1016/j.hjdsi.2015.09.009. [DOI] [PubMed] [Google Scholar]
  • 16.Pati S, Hussain M, Chauhan A, et al. Patient navigation pathway and barriers to treatment seeking in cancer in India: A qualitative inquiry. Cancer Epidemiol. 2017;37:973–978. doi: 10.1016/j.canep.2013.09.018. [DOI] [PubMed] [Google Scholar]
  • 17.Clinical Performance Surveillance Unit, Medical Care Quality Section, Medical Department Division, Ministry of Health . Technical Specifications Key Performance Indicators Clinical Services Medical Programme. Ministry of Health; 2014. [Google Scholar]
  • 18.Ramachandran A, Snyder FR, Katz ML, et al. Barriers to health care contribute to delays in follow-up among women with abnormal cancer screening: Data from the Patient Navigation Research Program. Cancer. 2015;121:4016–4024. doi: 10.1002/cncr.29607. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Hendren S, Griggs JJ, Epstein R, et al. Randomized controlled trial of patient navigation for newly diagnosed cancer patients: Effects on quality of life. Cancer Epidemiol Biomarkers Prev. 2012;21:1682–1690. doi: 10.1158/1055-9965.EPI-12-0537. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Baik SH, Gallo LC, Wells KJ. Patient navigation in breast cancer treatment and survivorship: A systematic review. J Clin Oncol. 2016;34:3686–3696. doi: 10.1200/JCO.2016.67.5454. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Luckett R, Pena N, Vitonis A, et al. Effect of patient navigator program on no-show rates at an academic referral colposcopy clinic. J Womens Health (Larchmt) 2015;24:608–615. doi: 10.1089/jwh.2014.5111. [DOI] [PubMed] [Google Scholar]
  • 22.Chan CM, Wan Ahmad WA, Md Yusof M, et al. Prevalence and characteristics associated with default of treatment and follow-up in patients with cancer. Eur J Cancer Care (Engl) 2015;24:938–944. doi: 10.1111/ecc.12312. [DOI] [PubMed] [Google Scholar]
  • 23.Ng TH, How SH, Kuan YC, et al. Defaulters among lung cancer patients in a suburban district in a developing country. Ann Thorac Med. 2012;7:12–15. doi: 10.4103/1817-1737.91556. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Wright EB, Holcombe C, Salmon P. Doctors’ communication of trust, care, and respect in breast cancer: Qualitative study. BMJ. 2004;328:864. doi: 10.1136/bmj.38046.771308.7C. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Chui P, Abdullah K, Wong L, et al. Prayer-for-health and complementary alternative medicine use among Malaysian breast cancer patients during chemotherapy. doi: 10.1186/1472-6882-14-425. http://www.biomedcentral.com/1472-6882/14/425 [DOI] [PMC free article] [PubMed]
  • 26.Taib NA, Yip CH, Low WY. A grounded explanation of why women present with advanced breast cancer. World J Surg. 2014;38:1676–1684. doi: 10.1007/s00268-013-2339-4. [DOI] [PubMed] [Google Scholar]
  • 27.Abdullah A, Abdullah KL, Yip CH, et al. The decision-making journey of Malaysian women with early breast cancer: A qualitative study. Asian Pac J Cancer Prev. 2013;14:7143–7147. doi: 10.7314/apjcp.2013.14.12.7143. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Global Oncology are provided here courtesy of American Society of Clinical Oncology

RESOURCES